Medicare Just Opened the GLP-1 Floodgates. Here's What It Means for the Market

For decades, federal law has prohibited Medicare from covering drugs prescribed for weight loss. On July 1, 2026, that changed. The Centers for Medicare and Medicaid Services (CMS) launched the Medicare GLP-1 Bridge — a time-limited demonstration program that, for the first time in the program's history, provides Medicare beneficiaries with access to obesity medications at a copay of $50 per month.

The implications for the pharmaceutical market, for Novo Nordisk and Eli Lilly, and for the federal budget are significant. This is the largest single expansion of drug access in the GLP-1 era — and it comes with an expiration date.

How the Bridge Works

The Medicare GLP-1 Bridge operates under Section 402 demonstration authority, which allows the HHS Secretary to test new approaches to care delivery without congressional action. It sidesteps the statutory ban on Medicare covering obesity drugs by functioning as a separate, taxpayer-funded demonstration outside the normal Part D framework.

Here's the mechanics: eligible Medicare beneficiaries with Part D coverage can access three drugs — Novo Nordisk's Wegovy (injection and tablet), Eli Lilly's Foundayo (oral tablet), and Lilly's Zepbound (KwikPen formulation only) — for a flat $50 monthly copay. That copay does not count toward the patient's Part D deductible or the $2,100 annual out-of-pocket cap, meaning it's a separate, additional cost for beneficiaries.

Behind the scenes, manufacturers agreed to a net price of $245 per 30-day supply under "most-favored-nation" deals struck with the Trump administration. CMS covers the difference between the $50 copay and the $245 net price — roughly $195 per patient per month. Part D plans bear no financial risk and have no role in determining eligibility. CMS contracted Humana to process prior authorizations centrally.

Who's Eligible — and How Big Is the Market?

The eligibility criteria are broader than many expected. Beneficiaries qualify if they have a BMI of 35 or higher, or a BMI of 27 or higher with at least one related condition — prediabetes, a previous heart attack or stroke, or blocked arteries in the arms or legs. The inclusion of prediabetes is notable: it positions GLP-1s as a diabetes prevention tool, not just a weight-loss intervention.

The addressable market is enormous. Chris Klomp, CMS Director of Medicare, said at the Aspen Ideas Festival that "several million" beneficiaries are expected to access GLP-1s through the Bridge program. Novo Nordisk and Eli Lilly estimate that 15 to 20 million older adults in Medicare qualify for weight-loss drugs under clinical criteria. Even at partial penetration, the revenue implications are staggering.

Consider the math: 3 million beneficiaries at a $245 net price for 12 months equals approximately $8.8 billion in annual drug spending. At 5 million beneficiaries — still well below the qualifying population — that figure approaches $15 billion. For context, Medicare's total gross spending on GLP-1s for already-covered indications (diabetes, cardiovascular disease, sleep apnea) was $27.5 billion in 2024 across 21.8 million claims. The Bridge could add a meaningful fraction on top of that within its first year.

The Winners: Novo Nordisk and Eli Lilly

The Bridge program consolidates the GLP-1 duopoly. Only three drugs are covered — two from Novo Nordisk and one from Eli Lilly. Competitors like Pfizer, Roche, and Biohaven, all of which have GLP-1 or GLP-1-adjacent assets in development, are not part of the program. That means the Bridge effectively directs a massive new patient population to the two incumbents for the duration of the demonstration.

For Novo Nordisk, this is a lifeline at a critical moment. The company has faced manufacturing constraints and competitive pressure from Lilly's dual-agonist franchise. The Bridge guarantees Wegovy a direct channel to millions of Medicare patients who previously had no coverage pathway. The oral Wegovy tablet — included in the Bridge — is particularly strategic, as it sidesteps injection-device manufacturing bottlenecks that have constrained supply.

For Eli Lilly, the inclusion of Foundayo (oral) and Zepbound (KwikPen) deepens the company's Medicare footprint. Lilly's decision to include only the KwikPen formulation of Zepbound was deliberate: the pen contains a month's supply in a single device, simplifying administration and prior authorization logistics. Foundayo, as a daily oral tablet, opens a channel for patients who prefer non-injectable options — a population that Novo's Wegovy tablet also targets.

The Fiscal Question Nobody's Answering

The Bridge runs through December 31, 2027 — 18 months. But the fiscal trajectory it sets in motion extends far beyond that window.

CMS is funding the demonstration directly from taxpayer dollars, not through Part D plan premiums. At $195 per patient per month in CMS subsidy costs, even 3 million enrollees would cost the federal government approximately $7 billion over 18 months. At 5 million, the cost approaches $12 billion. And those figures assume stable enrollment — if adoption ramps faster than expected, the fiscal exposure grows proportionally.

The broader question is what happens when the demonstration expires. The BALANCE Model — a CMMI program that was supposed to provide permanent Medicare and Medicaid coverage of GLP-1s for obesity starting in January 2027 — has been indefinitely delayed. Without legislative action to lift the statutory prohibition on Medicare covering obesity drugs, coverage ends on December 31, 2027. Patients who begin therapy under the Bridge may face the prospect of losing access in 18 months.

This is not a theoretical concern. GLP-1s for obesity are widely understood to be chronic therapies — discontinuation typically leads to weight regain. A time-limited coverage program that starts millions of patients on a lifelong medication and then cuts off access creates a clinical cliff. The political pressure to extend or replace the Bridge will be immense, and that pressure will fall on Congress, not CMS.

What This Means for the Investment Thesis

For investors evaluating the GLP-1 market, the Bridge program has three key implications:

1. Near-term revenue acceleration for incumbents. Both Novo and Lilly are about to see a significant uptick in Medicare prescriptions. The $245 net price is lower than current list prices but higher than what many cash-pay patients are spending through manufacturer discount programs. The net effect on revenue per prescription is mixed, but the volume effect is unambiguously positive — millions of previously uninsured patients now have a pathway.

2. Pricing ceiling established. The $245 net price negotiated under the Bridge sets a reference point that will influence commercial payer negotiations, Medicaid pricing, and international benchmarking. It also intersects with the Medicare Drug Price Negotiation Program, which selected semaglutide for negotiation in 2025 with a negotiated price taking effect in 2027. The compounding effect of these pricing pressures will compress margins even as volumes grow.

3. Political risk is now the dominant variable. The GLP-1 market's growth trajectory is no longer driven primarily by clinical data or manufacturing capacity. It's driven by government policy. Whether the Bridge is extended, whether Congress lifts the obesity drug coverage ban, whether the BALANCE Model is implemented — these are political questions that will determine the addressable market for the next decade. Investors who model GLP-1 revenue without incorporating policy risk are missing the largest swing factor.

The Bottom Line

The Medicare GLP-1 Bridge is the most significant expansion of drug access in the obesity market's history. It directs millions of patients to two companies at a taxpayer-subsidized price point, and it does so through a legal mechanism that bypasses Congress entirely. The 18-month clock is now running. Between now and December 31, 2027, Novo Nordisk and Eli Lilly will capture the bulk of the benefit. After that, the market's trajectory depends on decisions that haven't been made yet — by CMS, by Congress, and by the next administration.

For the biotech sector more broadly, the Bridge demonstrates that the federal government is willing to use demonstration authority aggressively to expand access to high-cost therapies — and to negotiate prices directly with manufacturers. That precedent extends well beyond GLP-1s. Any company with a high-cost therapy targeting a large Medicare-eligible population should be paying close attention to how this program evolves.

---

Todd Colpron is the Managing Partner of Eliakim Capital, a private investment and strategic advisory firm that manages its own capital while working alongside select family offices and private investors to identify and support exceptional opportunities.